The report found the following.
1. Xigris is the only therapeutic product currently approved in the U.S. for treating sepsis, but it is not widely accepted due to concerns about its high cost, adverse effects and efficacy.
2. Going forward, the market for sepsis therapeutics will be driven by a rise in the geriatric population and growing incidence of sepsis among these elderly patients.
3. Additionally, numerous therapeutic drugs under different phases of clinical trials and innovations in treatment options for treating septic shock will drive the growth of the market.
4. A major challenge that could hinder growth in the sepsis therapeutics market is the lack of early diagnostic tests for detecting the condition and the lack of awareness among patients.
5. Geographically, the biggest market for sepsis therapeutics is North America, followed by Europe and Asia. North America has a high incidence of sepsis disorder and a growing patient awareness about sepsis complications.
More articles on sepsis:
Bill Clinton shares family story of medical error at patient safety summit
Alabama hospital implements new protocols to cut sepsis mortality in half
ZDoggMD delivers holiday-themed ‘It’s Beginning to Look a Lot Like Sepsis’ music video
